









Markets
/
Stocks
/
nasdaq-gnlx
/

Genelux Corp

GNLX

2.390USD

+0.040+1.70%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

89.90MMarket Cap

LossP/E TTM



Genelux Corp

2.390

+0.040+1.70%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Genelux Corp

Currency: USD Updated: 2026-02-06

Key Insights

Genelux Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 185 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.33.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Genelux Corp's Score

Industry at a Glance

Industry Ranking

185 / 392

Overall Ranking

353 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Genelux Corp Highlights

StrengthsRisks

Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.

Growing

The company is in a growing phase, with the latest annual income totaling USD 8.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 8.00K.

Overvalued

The company’s latest PE is -2.70, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 12.03M shares, increasing 14.14% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 62.90K shares of this stock.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

19.333

Target Price

+722.69%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Genelux Corp is 6.63, ranking 233 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.63

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.07

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.69

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.36

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Genelux Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Genelux Corp is 6.02, ranking 341 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.70, which is -36.50% below the recent high of -1.72 and -1894.06% above the recent low of -53.93.

Score

Industry at a Glance

Previous score

6.02

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 185/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Genelux Corp is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 31.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

19.333

Target Price

+722.69%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Genelux Corp

GNLX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Genelux Corp is 3.85, ranking 359 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.87 and the support level at 2.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.81

Change

0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.055

Neutral

RSI(14)

28.513

Sell

STOCH(KDJ)(9,3,3)

12.780

Oversold

ATR(14)

0.190

Low Volatility

CCI(14)

-168.319

Sell

Williams %R

90.662

Oversold

TRIX(12,20)

-1.505

Sell

StochRSI(14)

24.502

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.554

Sell

MA10

2.674

Sell

MA20

2.707

Sell

MA50

3.702

Sell

MA100

4.633

Sell

MA200

3.857

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Genelux Corp is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 26.90%, representing a quarter-over-quarter increase of 32.43%. The largest institutional shareholder is The Vanguard, holding a total of 1.55M shares, representing 3.47% of shares outstanding, with 2.52% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Armistice Capital LLC

4.22M

Szalay (Aladar)

3.17M

-7.09%

Woodward Diversified Capital, LLC

1.84M

+3.70%

The Vanguard Group, Inc.

Star Investors

1.42M

-2.37%

Bleichroeder LP

714.00K

Zindrick (Thomas)

636.10K

-0.70%

Thomas (John)

492.78K

-1.99%

BlackRock Institutional Trust Company, N.A.

373.57K

+17.45%

Geode Capital Management, L.L.C.

353.84K

+10.98%

BofA Global Research (US)

323.49K

-20.85%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Genelux Corp is 1.61, ranking 300 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Genelux Corp’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.